^
Association details:
Biomarker:No biomarker
Cancer:Chronic Lymphocytic Leukemia
Drug:Rituxan (rituximab) (CD20 inhibitor) +
lenalidomide (TNFα inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Chronic lymphocytic leukemia/Small lymphocytic lymphoma…Other recommended regimens…Lenalidomide ± rituximab